{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:24:09Z","timestamp":1790346249397,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.lanepe.2024.100923","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T23:36:01Z","timestamp":1715643361000},"page":"100923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-4834","authenticated-orcid":false,"given":"Tessel M.","family":"Boertien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine L.","family":"Drent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Booij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B.L.M.","family":"Majoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel P.M.","family":"Stokkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jantien","family":"Hoogmoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke R.","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suat","family":"Simsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald Groote","family":"Veldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick J.","family":"Weterings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Vink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.T.","family":"Tanck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Fliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Bisschop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2024.100923_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11102-018-0869-3","article-title":"Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas","volume":"21","author":"Ntali","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.lanepe.2024.100923_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.lanepe.2024.100923_bib3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11102-022-01235-x","article-title":"The NETting of pituitary adenoma: a gland illusion","volume":"25","author":"Ho","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.lanepe.2024.100923_bib4","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jc.2008-0643","article-title":"Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas","volume":"93","author":"Dekkers","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.lanepe.2024.100923_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11102-011-0347-7","article-title":"Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis","volume":"15","author":"Roelfsema","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.lanepe.2024.100923_bib6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000339823","article-title":"Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis","volume":"96","author":"Chen","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.lanepe.2024.100923_bib7","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/EJE-17-0216","article-title":"Management of endocrine disease: present and future perspectives for medical therapy of nonfunctioning pituitary adenomas","volume":"177","author":"Greenman","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lanepe.2024.100923_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s42000-018-0070-0","article-title":"Medical therapy for non-functioning pituitary tumors\u2014a critical approach","volume":"18","author":"Tampourlou","year":"2019","journal-title":"Hormones (Basel)"},{"key":"10.1016\/j.lanepe.2024.100923_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1530\/EJE-16-0206","article-title":"Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists","volume":"175","author":"Greenman","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lanepe.2024.100923_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/COC.0000000000000505","article-title":"Cabergoline in the management of residual nonfunctioning pituitary adenoma","volume":"42","author":"Batista","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.lanepe.2024.100923_bib11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11102-011-0370-8","article-title":"Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study","volume":"15","author":"Fusco","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.lanepe.2024.100923_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1530\/ERC-14-0472","article-title":"SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary","volume":"22","author":"Lee","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.lanepe.2024.100923_bib13","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1210\/jc.2011-3163","article-title":"Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study","volume":"97","author":"Ram\u00edrez","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.lanepe.2024.100923_bib14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1365-2265.1997.3361119.x","article-title":"Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide","volume":"47","author":"Borson-Chazot","year":"1997","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lanepe.2024.100923_bib15","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","article-title":"Somatostatin receptor sst1-sst 5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands","volume":"28","author":"Reubi","year":"2001","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.lanepe.2024.100923_bib16","doi-asserted-by":"crossref","first-page":"D15","DOI":"10.1530\/EJE-18-0549","article-title":"Is receptor profiling useful for predicting pituitary therapy?","volume":"179","author":"Marazuela","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lanepe.2024.100923_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000472563","article-title":"A\u00a0critical evaluation of sst3 and sst5 immunohistochemistry in human pituitary adenomas","volume":"106","author":"K\u00f6rner","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.lanepe.2024.100923_bib18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.mce.2007.12.011","article-title":"Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas","volume":"286","author":"Padova","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.lanepe.2024.100923_bib19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1530\/eje.0.1410396","article-title":"Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in\u00a0vitro","volume":"141","author":"Florio","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lanepe.2024.100923_bib20","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1677\/ERC-08-0181","article-title":"Medical therapy for clinically non-functioning pituitary adenomas","volume":"15","author":"Colao","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.lanepe.2024.100923_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11102-006-0270-5","article-title":"Somatostatin receptor imaging for neuroendocrine tumors","volume":"9","author":"de Herder","year":"2006","journal-title":"Pituitary"},{"key":"10.1016\/j.lanepe.2024.100923_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use","volume":"27","author":"Reubi","year":"2000","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.lanepe.2024.100923_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038250","article-title":"The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68Ga -DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size","volume":"10","author":"Boertien","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.lanepe.2024.100923_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lanepe.2024.100923_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41824-020-0073-3","article-title":"68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas","volume":"4","author":"Boertien","year":"2020","journal-title":"Eur J Hybrid Imaging"},{"key":"10.1016\/j.lanepe.2024.100923_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MNM.0b013e32833f635e","article-title":"Distribution pattern of 68Ga-DOTATATE in disease-free patients","volume":"31","author":"Shastry","year":"2010","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.lanepe.2024.100923_bib27","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0895-4356(98)00097-3","article-title":"Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations","volume":"51","author":"Aaronson","year":"1998","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.lanepe.2024.100923_bib28","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","article-title":"User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability","volume":"31","author":"Yushkevich","year":"2006","journal-title":"Neuroimage"},{"key":"10.1016\/j.lanepe.2024.100923_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/eje.1.02334","article-title":"The natural course of non-functioning pituitary macroadenomas","volume":"156","author":"Dekkers","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lanepe.2024.100923_bib30","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.lanepe.2024.100923_bib31","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jclinepi.2007.02.006","article-title":"A\u00a0simple sample size formula for analysis of covariance in randomized clinical trials","volume":"60","author":"Borm","year":"2007","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.lanepe.2024.100923_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13063-018-3108-3","article-title":"The correlation between baseline score and post-intervention score, and its implications for statistical analysis","volume":"20","author":"Clifton","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.lanepe.2024.100923_bib34","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2024.100923_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40268-021-00342-7","article-title":"Incident gallstones during somatostatin analog treatment are associated with acute biliary complications especially after discontinuation","volume":"21","author":"Aapkes","year":"2021","journal-title":"Drugs R"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224000905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224000905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T08:24:49Z","timestamp":1721118289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776224000905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":34,"alternative-id":["S2666776224000905"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100923","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.100923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100923"}}